The Globe and Mail reports in its Thursday edition that Ro, once focused on sexual wellness treatments, has shifted to offering weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound as part of a healthcare revolution. A New York Times dispatch to The Globe reports that now, the nine-year-old privately held Ro is offering a closer look at the results of that transition. Ro said Wednesday it had more than $3-billion (U.S.) in annualized revenue, up nearly tenfold since it revamped its business starting in 2022. For Ro founder and chief executive officer Zachariah Reitano the results underscore both the efficacy of the company's overhaul and the huge draw of GLP-1 drugs, which can offer benefits beyond weight loss. The company's turnaround may also spur questions about whether Ro, which has not raised new money from investors in years, will eventually go public, following in the footsteps of its rival Hims and Hers. Mr. Reitano chalked up Ro's success to what he called a badly needed reset. That came months after the company raised $500-million (U.S.) at a $5-billion (U.S.) valuation in spring 2021. Mr. Ro claims that Ro is now the largest provider of branded GLP-1 drugs in the United States.